Zhibo Zhang

5PUBLICATIONS
5CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 11, 2023
Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.

Jiangyue Lu, Xiao Lei, Pei Zhang

|Mar 23, 2023
Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.

Jiangyue Lu, Lehui Du, Xiao Lei

|Mar 22, 2022
First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.

Jinzhao Zhai, Jiangyue Lu, Zhibo Zhang

|Nov 23, 2020
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

Zhibo Zhang, Fan Zhang, Fang Yuan

|Nov 11, 2020
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Shixue Chen, Ziwei Huang, Wangping Jia

Pageof 1

Frequent Collaborators

2 joint publications

Xiao Lei

1 joint publications

Qiuxiang Ou

1 joint publications

Jinzhao Zhai

1 joint publications

Xiaoyu Zhi